NCT00417170 - Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

High Blood PressureMetabolic SyndromeInsulin ResistanceEndothelial Dysfunction

Interventions

DRUG

Aliskiren

Aliskiren 300 mg tablets taken orally once daily

DRUG

Amlodipine

Amlodipine 5 mg capsule taken orally once daily

DRUG

Placebo Aliskiren

Placebo Aliskiren taken orally once daily.

DRUG

Placebo Amlodipine

Placebo Amlodipine taken orally once daily

Trial Locations (1)

Novartis Investigative Site, Santa Monica